Slingshot members are tracking this event:

Bayer Phase 3 program called RESPIRE of Cipro DPI (Cipro Dry Powder Inhaler) for Non-cystic fibrosis bronchiectasis data due 2H 2016

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
NKTR Community voting in process

Additional Information

Additional Relevant Details We will receive a flat 30% royalty on U.S. sales in an average of 22% on ex-U.S. sales. This level of royalty is the equivalent of owning half of the drug. Cipro DPI is targeting non-cystic fibrosis bronchiectasis or NCFB, the Phase 3 RESPIRE program features two 48-week multinational randomized placebo control studies with data expected in the second half of 2016. The market for Cipro DPI is estimated to be about $750 million and Nektar will receive an average 10% royalty on net sales.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 24, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Program, Respire, Cipro Dpi, Dry Powder Inhaler, Non-cysticc Fribrosis Bronchiectasis, Ncfb, 2h 2016